Export of SK Plasma No.1 Blood Product Factory
Investment of 300 Billion KRW
Annual Processing Capacity of 1 Million Liters of Plasma
SK Plasma is building a blood fractionation plant worth 300 billion KRW in Indonesia.
Perspective view of the blood product factory SK Plasma will build in Indonesia. [Photo by SK Plasma]
On the 8th, SK Plasma announced that it has received final approval from the Indonesian Ministry of Health for the construction of a plasma fractionation plant. The total scale of the blood fractionation plant to be built locally in Indonesia is approximately 250 million USD (about 300 billion KRW), capable of processing 1 million liters of raw plasma annually.
Along with establishing the local plant, SK Plasma will transfer blood fractionation and other blood product-related technologies. Furthermore, it will be responsible for the plant’s operation as well as the production and sales of the products. Blood products are pharmaceuticals derived from blood, manufactured by fractionating and purifying components within the blood into forms such as albumin and immunoglobulin. These products are essential treatments used in various fields including shock due to excessive bleeding, congenital immunodeficiency disorders, and hemophilia. Especially in national disaster situations, blood products like albumin and immunoglobulin are widely needed and are designated as essential national medicines for management.
SK Plasma will collaborate with its affiliate SK Eco Engineering to build the plant. A company official explained, “We have already completed site selection and basic design in advance, so we expect to complete construction and operation of the plant within the deadline required by the Indonesian government.” The official added that after the plant’s completion, exclusive supply of blood products locally will be possible in accordance with relevant regulations.
SK Plasma explained that this project was achieved through collaboration with the Ministry of Health and Welfare of the Republic of Korea. During discussions between the health authorities of both countries on health and medical issues, cooperation on blood products was initiated, leading to SK Plasma building a local plant for Indonesia’s own production of blood products. The Indonesian government plans to produce blood products using plasma from Indonesian citizens through SK Plasma’s local plant to ensure stable supply of essential medicines. Currently, Indonesia relies entirely on imports for blood products.
Seungjoo Kim, CEO of SK Plasma, said, “This plant expansion is a case of realizing ESG (Environmental, Social, and Governance) and business viability simultaneously by transferring technology to countries that do not have their own blood product development and manufacturing infrastructure.” He added, “We will continue to promote ESG-based strategies that enhance social value while transferring the latest know-how such as eco-friendly design.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
